Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) is a medical technology company focused on advancing the surgical management of bunion and related midfoot deformities. As a commercial‑stage orthopaedic device company with a portfolio centered on 3D bunion correction, Treace regularly issues news on product innovation, clinical evidence, financial performance and capital structure.
On this page, readers can follow TMCI news covering quarterly and annual financial results, revenue trends, liquidity updates and guidance changes, as reported in the company’s earnings releases and related Form 8‑K filings. These updates often discuss factors such as surgeon adoption of Treace’s expanded bunion technology portfolio, procedure volume dynamics and the impact of broader economic conditions on elective bunion surgery.
Treace also announces new technologies and product milestones, including developments in its Lapiplasty 3D Bunion Correction System, minimally invasive systems such as Nanoplasty and Percuplasty, the SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants and IntelliGuide patient specific planning and cut guide technology. News items may highlight first surgical cases with new platforms, transitions from limited market release to full market release and surgeon feedback on workflow and clinical use.
In addition, TMCI news includes updates on clinical studies like ALIGN3D and MTA3D, where interim data on radiographic correction, recurrence, pain and patient‑reported outcomes are presented at orthopedic conferences. Investors can also see announcements about debt financing arrangements, investor conferences, investor days and changes in board composition or governance roles.
For investors, clinicians and analysts tracking TMCI stock, this news feed offers a consolidated view of Treace’s financial disclosures, product pipeline developments and market‑facing activities related to bunion and midfoot deformity surgery.
Treace Medical Concepts (TMCI) has filed a lawsuit against Fusion Orthopedics in the U.S. District Court for Arizona, claiming infringement on several patents related to its Lapiplasty® 3D Bunion Correction™ system. The lawsuit includes allegations of copyright infringement, trademark rights violation, and unfair competition, seeking both injunctive relief and damages. CEO John T. Treace emphasized the importance of their intellectual property, which supports continued innovation in bunion treatment, benefiting thousands of patients.
Treace Medical Concepts (TMCI) reported strong financial results for Q4 and full year 2021. Q4 revenue hit $33.4 million, a 39% year-over-year increase, with full year revenue reaching $94.4 million, up 65%. Gross margins improved to 81.1% in Q4, reflecting higher sales volume and pricing. The company made strategic investments in sales and marketing, contributing to a 58% direct sales channel revenue in Q4. Despite these gains, TMCI reported a net loss of ($6.6) million for Q4 and ($20.7) million for 2021. The outlook for 2022 anticipates revenue of $125 million to $130 million.
Treace Medical Concepts (TMCI) has presented the latest interim analysis from the ALIGN3D clinical study at the 2022 ACFAS Annual Scientific Conference. The analysis included data from 160 participants, demonstrating a return to weight-bearing in 8.5 days and significant improvements in pain reduction and quality of life after 12 and 24 months following the Lapiplasty procedure. Notably, the recurrence rates were low at 0.9% and 0.0% at 12 and 24 months, respectively. CEO John T. Treace expressed commitment to advancing clinical evidence supporting their solutions for bunion patients.
Treace Medical Concepts (TMCI) announces new product innovations at the 2022 ACFAS Annual Scientific Conference in Austin, Texas, from February 24-27. Key highlights include:
- Lapiplasty® 3-n-1™ Guide: A precision instrument designed to enhance the efficiency of the bunion correction procedure.
- Adductoplasty™ Midfoot Correction System: Expansion of the system to improve efficiency and treat various midfoot conditions.
- Lapiplasty® S4A Anatomic Plating System: Next-generation titanium plates for improved surgical outcomes.
- SpeedRelease™ and TriTome™ Instruments: New cutting tools for enhanced surgical release.
Treace Medical Concepts (NasdaqGS: TMCI) will announce its financial results for Q4 and the full year of 2021 on March 3, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET, where management will discuss these results. Interested investors can join the call by dialing (888) 708-0264 domestically or (720) 405-2122 internationally, using Conference ID: 6356356. Treace is known for the Lapiplasty® 3D Bunion Correction™ System and recently introduced the Adductoplasty™ Midfoot Correction System to enhance treatment options for bunion deformities.
Treace Medical Concepts (TMCI) announced the podium presentation of interim analysis data from its ALIGN3D™ clinical study at the ACFAS Annual Scientific Conference from February 24-27, 2022, in Austin, Texas. The presentation, led by Dr. George Tye Liu, will focus on a five-year multicenter study evaluating outcomes of the Lapiplasty® 3D Bunion Correction™. The study, involving 173 patients, aims to assess the effectiveness of correcting hallux valgus deformity with a focus on various clinical outcomes. Final follow-up for primary endpoints is expected in the first half of 2023.
Treace Medical Concepts (TMCI) announced the granting of U.S. Patent No. 11,213,333 for its innovative bunion correction technology. This patent enhances Treace's robust patent portfolio, which includes over 40 granted patents and more than 50 pending applications globally. The patent covers a technique utilizing a bone preparation and positioning guide for bunion correction, further solidifying Treace's commitment to surgical innovation. CEO John T. Treace emphasized the significance of this patent in advancing treatment options for bunion patients.
Treace Medical Concepts (TMCI) announced preliminary unaudited revenue results for Q4 and full year 2021, projecting revenues between $33.1 million to $33.4 million for Q4 and $94.1 million to $94.4 million for the year, marking a growth of 37% to 39% and 64% to 65% year-over-year, respectively. The company highlights a 53% to 54% sequential revenue increase from Q3 2021. CEO John T. Treace expressed confidence in their market position and the effectiveness of their Lapiplasty® System. Financial guidance for 2022 is expected during their upcoming earnings call.
Treace Medical Concepts (Nasdaq: TMCI) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2022, at 4:30 p.m. ET. CEO John T. Treace and CFO Mark L. Hair will present at this prominent event. A live webcast and replay will be accessible on the company's Investor Relations website. Treace specializes in orthopedic medical devices aimed at treating bunions, highlighting their patented Lapiplasty® 3D Bunion Correction™ system and the Adductoplasty™ Midfoot Correction System.
Treace Medical Concepts, Inc. (Nasdaq: TMCI) announced the granting of U.S. Patent No. 11,185,359 for a "Bone Positioning Guide" related to bunion correction surgery. Additionally, the U.S. Patent Office issued a Notice of Allowance for a pending application on similar techniques. These developments enhance Treace's patent portfolio, which now includes over 35 granted patents and 60 pending applications globally. CEO John T. Treace emphasized the importance of these patents in reinforcing the company's commitment to innovation in bunion surgery.